RU2692479C2 - (5,6-дигидро)пиримидо[4,5-е]индолизины - Google Patents

(5,6-дигидро)пиримидо[4,5-е]индолизины Download PDF

Info

Publication number
RU2692479C2
RU2692479C2 RU2016141405A RU2016141405A RU2692479C2 RU 2692479 C2 RU2692479 C2 RU 2692479C2 RU 2016141405 A RU2016141405 A RU 2016141405A RU 2016141405 A RU2016141405 A RU 2016141405A RU 2692479 C2 RU2692479 C2 RU 2692479C2
Authority
RU
Russia
Prior art keywords
carboxamide
dihydropyrimido
anilino
methoxy
indolysin
Prior art date
Application number
RU2016141405A
Other languages
English (en)
Russian (ru)
Other versions
RU2016141405A3 (enExample
RU2016141405A (ru
Inventor
Ман Адрианус Петрус Антониус де
Рогир Христиан БЁЙСМАН
Ян Герард СТЕРРЕНБУРГ
Йост Корнелис Маринус ЭЙТДЕХАГ
ВИТ Юри Йоханнес Петрус ДЕ
Гёйдо Енни Рюдолф ЗАМАН
Original Assignee
Недерлэндс Транслэшинал Рисерч Сентер Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Недерлэндс Транслэшинал Рисерч Сентер Б.В. filed Critical Недерлэндс Транслэшинал Рисерч Сентер Б.В.
Publication of RU2016141405A publication Critical patent/RU2016141405A/ru
Publication of RU2016141405A3 publication Critical patent/RU2016141405A3/ru
Application granted granted Critical
Publication of RU2692479C2 publication Critical patent/RU2692479C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2016141405A 2014-04-07 2015-03-30 (5,6-дигидро)пиримидо[4,5-е]индолизины RU2692479C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14163734 2014-04-07
EP14163734.8 2014-04-07
EP15153207.4 2015-01-30
EP15153207 2015-01-30
PCT/EP2015/056839 WO2015155042A1 (en) 2014-04-07 2015-03-30 (5,6-dihydro)pyrimido[4,5-e]indolizines

Publications (3)

Publication Number Publication Date
RU2016141405A RU2016141405A (ru) 2018-05-07
RU2016141405A3 RU2016141405A3 (enExample) 2018-10-02
RU2692479C2 true RU2692479C2 (ru) 2019-06-25

Family

ID=52774240

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016141405A RU2692479C2 (ru) 2014-04-07 2015-03-30 (5,6-дигидро)пиримидо[4,5-е]индолизины

Country Status (16)

Country Link
US (3) USRE50082E1 (enExample)
EP (1) EP3129374B1 (enExample)
JP (1) JP6518690B2 (enExample)
KR (1) KR102432420B1 (enExample)
CN (1) CN106132963B (enExample)
AU (1) AU2015243694B2 (enExample)
BR (1) BR112016022342B1 (enExample)
CA (1) CA2944610C (enExample)
DK (1) DK3129374T3 (enExample)
ES (1) ES2716165T3 (enExample)
HU (1) HUE043108T2 (enExample)
MX (1) MX368767B (enExample)
PL (1) PL3129374T3 (enExample)
PT (1) PT3129374T (enExample)
RU (1) RU2692479C2 (enExample)
WO (1) WO2015155042A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2852026C2 (ru) * 2022-03-04 2025-12-02 Силладжен, Инк. Фармацевтические комбинации для применения при лечении неопластических заболеваний

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3129374B1 (en) * 2014-04-07 2018-12-19 Netherlands Translational Research Center B.V. (5,6-dihydro)pyrimido[4,5-e]indolizines
CN114592061A (zh) 2015-04-17 2022-06-07 荷兰转化研究中心有限责任公司 用于ttk抑制剂化疗的预后生物标记
US10758530B2 (en) * 2016-02-19 2020-09-01 Phoenix Molecular Designs Carboxamide derivatives useful as rsk inhibitors
MA45189A (fr) 2016-06-07 2019-04-10 Jacobio Pharmaceuticals Co Ltd Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2
CN106551938B (zh) * 2016-11-26 2017-11-24 广东安诺药业股份有限公司 一种治疗非酒精性脂肪肝的药物及其应用
HRP20241239T1 (hr) 2017-03-23 2024-12-06 Jacobio Pharmaceuticals Co., Ltd. Novi heterociklički derivati korisni kao shp2 inhibitori
US20210393623A1 (en) 2018-09-26 2021-12-23 Jacobio Pharmaceuticals Co., Ltd. Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors
US12378245B2 (en) 2019-02-11 2025-08-05 Phoenix Molecular Designs Crystalline forms of an RSK inhibitor
JP2024546977A (ja) * 2021-12-15 2024-12-26 シルラジェン,インコーポレイテッド 新生物疾患の処置方法
WO2023113477A1 (en) * 2021-12-15 2023-06-22 Sillajen, Inc. Pharmaceutical combinations for use in the treatment of neoplastic diseases
EP4448017A4 (en) * 2021-12-15 2025-12-24 Sillajen Inc PHARMACEUTICAL COMPOSITIONS CONTAINING MODIFIED BETA-CYCLODEXTRINS
AU2023228543A1 (en) * 2022-03-04 2024-08-22 Sillajen, Inc. Pharmaceutical combinations for use in the treatment of neoplastic diseases.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA007983B1 (ru) * 2001-09-19 2007-02-27 Авентис Фарма С.А. Индолизины в качестве ингибиторов киназных белков
WO2009156315A1 (en) * 2008-06-26 2009-12-30 Nerviano Medical Sciences S.R.L. Pyrazolo-quinazolines
WO2012101032A1 (en) * 2011-01-26 2012-08-02 Nerviano Medical Sciences S.R.L. Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA13170A (en) 2003-05-22 2006-12-13 Pharmacia Italia Spa Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors.
EP2118102B1 (en) 2006-11-28 2013-06-12 Nerviano Medical Sciences S.r.l. Tricyclic indoles and (4,5-dihydro) indoles
WO2010111406A2 (en) 2009-03-24 2010-09-30 Myriad Pharmaceuticals, Inc. Compounds and therapeutic uses thereof
EP2424868B1 (en) 2009-04-29 2018-01-10 Nerviano Medical Sciences S.r.l. Cdk inhibitor salts
CN102470136B (zh) 2009-07-29 2013-12-25 内尔维阿诺医学科学有限公司 Plk 抑制剂的盐类
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
JP2014503521A (ja) * 2010-12-17 2014-02-13 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 過増殖性障害の処置におけるmps−1およびtkk阻害剤としての使用のための、イミダゾピラジン類
JP6523267B2 (ja) 2013-06-24 2019-05-29 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Fshrの調節剤としてのイミダゾール化合物及びその使用
EP3129374B1 (en) * 2014-04-07 2018-12-19 Netherlands Translational Research Center B.V. (5,6-dihydro)pyrimido[4,5-e]indolizines

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA007983B1 (ru) * 2001-09-19 2007-02-27 Авентис Фарма С.А. Индолизины в качестве ингибиторов киназных белков
WO2009156315A1 (en) * 2008-06-26 2009-12-30 Nerviano Medical Sciences S.R.L. Pyrazolo-quinazolines
WO2012101032A1 (en) * 2011-01-26 2012-08-02 Nerviano Medical Sciences S.R.L. Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2852026C2 (ru) * 2022-03-04 2025-12-02 Силладжен, Инк. Фармацевтические комбинации для применения при лечении неопластических заболеваний

Also Published As

Publication number Publication date
HUE043108T2 (hu) 2019-07-29
US20170096432A1 (en) 2017-04-06
WO2015155042A1 (en) 2015-10-15
ES2716165T3 (es) 2019-06-10
DK3129374T3 (en) 2019-04-08
CN106132963A (zh) 2016-11-16
MX368767B (es) 2019-10-15
KR102432420B1 (ko) 2022-08-17
BR112016022342B1 (pt) 2022-10-04
JP6518690B2 (ja) 2019-05-22
BR112016022342A2 (pt) 2017-08-15
AU2015243694A1 (en) 2016-11-03
AU2015243694B2 (en) 2019-01-17
EP3129374A1 (en) 2017-02-15
RU2016141405A3 (enExample) 2018-10-02
CN106132963B (zh) 2019-08-06
US9856258B2 (en) 2018-01-02
PL3129374T3 (pl) 2019-07-31
BR112016022342A8 (pt) 2021-07-20
EP3129374B1 (en) 2018-12-19
RU2016141405A (ru) 2018-05-07
CA2944610C (en) 2024-01-09
MX2016012997A (es) 2016-12-07
CA2944610A1 (en) 2015-10-15
KR20170013866A (ko) 2017-02-07
PT3129374T (pt) 2019-03-25
JP2017510595A (ja) 2017-04-13
USRE48974E1 (en) 2022-03-15
USRE50082E1 (en) 2024-08-20

Similar Documents

Publication Publication Date Title
RU2692479C2 (ru) (5,6-дигидро)пиримидо[4,5-е]индолизины
CN114269735B (zh) 二氢或四氢喹唑啉类化合物及其中间体、制备方法和应用
CN103889962B (zh) 作为受体酪氨酸激酶btk抑制剂的取代的n‑(3‑(嘧啶‑4‑基)苯基)丙烯酰胺类似物
EP3173412B1 (en) 2,4-disubstituted 7h-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof
JP2022516469A (ja) ユビキチン特異的プロテアーゼ1を阻害するための組成物
EP3621968A1 (en) Heteroaryl compounds that inhibit g12c mutant ras proteins
KR20170101908A (ko) 피리미딘 또는 피리딘계 화합물, 이의 제조방법 및 약학적 용도
KR20130096241A (ko) Alk 억제제로서 4-(1h-인돌-3-일)-피리미딘
AU2013344049A1 (en) ALK kinase inhibitors
ES2878078T3 (es) Inhibidores de GSK-3
EP3169687B1 (en) FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS
WO2023110970A1 (en) Macrocyclic btk inhibitors
CN104837844A (zh) 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪
CN112313207A (zh) 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用
ES2905985T3 (es) Compuesto de oxazino-quinazolina y de tipo oxazino-quinazolina, método de preparación y usos de los mismos
AU2016293841B2 (en) Fused quinoline compunds as pi3k/mTor inhibitors
CN103570731A (zh) 嘧啶并三环或嘧啶并四环类化合物及其药用组合物和应用
HK1231072A1 (en) (5,6-dihydro)pyrimido[4,5-e]indolizines
HK1231072B (zh) (5,6-二氢)嘧啶并[4,5-e]吲嗪
EA047866B1 (ru) Ингибиторы мутантных белков kras
WO2022070071A1 (en) Dihydroorotate dehydrogenase inhibitors
HK40042713A (en) Oxazino-quinazoline and oxazino-quinazoline type compound, preparation method therefor, and uses thereof
HK40042713B (en) Oxazino-quinazoline and oxazino-quinazoline type compound, preparation method therefor, and uses thereof